| Corticosteroids for COVID-19: the search for an optimum duration of therapy | Lancet Respiratory Medicine | 23 hours | save |  |  |  |  |
| Herd immunity for COVID-19 | Lancet Respiratory Medicine | 3 days | save | | | | |
| US presidential election results, and the future of WHO and the Paris Agreement | Lancet Respiratory Medicine | 3 days | save | | | | |
| Clinical trials in critical care: can a Bayesian approach enhance clinical and scientific decision making? | Lancet Respiratory Medicine | 7 days | save | | | | |
| Beyond the clot: perfusion imaging of the pulmonary vasculature after COVID-19 | Lancet Respiratory Medicine | 10 days | save | | | | |
| Trajectories of asthma and allergies from 7 years to 53 years and associations with lung function and extrapulmonary comorbidity profiles: a prospective cohort study | Lancet Respiratory Medicine | 10 days | save | | | | |
| Provision of holistic care after severe COVID-19 pneumonia: anticipating clinical need and managing resources | Lancet Respiratory Medicine | 14 days | save | | | | |
| Pathophysiology of COVID-19-associated acute respiratory distress syndrome | Lancet Respiratory Medicine | 14 days | save | | | | |
| Pathophysiology of COVID-19-associated acute respiratory distress syndrome | Lancet Respiratory Medicine | 14 days | save | | | | |
| Pathophysiology of COVID-19-associated acute respiratory distress syndrome | Lancet Respiratory Medicine | 14 days | save | | | | |
| Pathophysiology of COVID-19-associated acute respiratory distress syndrome | Lancet Respiratory Medicine | 14 days | save | | | | |
| Telomere length and risk of idiopathic pulmonary fibrosis and chronic obstructive pulmonary disease: a mendelian randomisation study | Lancet Respiratory Medicine | 14 days | save | | | | |
| Pathophysiology of COVID-19-associated acute respiratory distress syndrome – Authors' reply | Lancet Respiratory Medicine | 14 days | save | | | | |
| Implementing rapid diagnostics for COVID-19 | Lancet Respiratory Medicine | 15 days | save | | | | |
| Nebulised interferon beta-1a for patients with COVID-19 | Lancet Respiratory Medicine | 15 days | save | | | | |
| Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial | Lancet Respiratory Medicine | 15 days | save | | | | |
| Confronting a rare ovarian cancer during lockdown | Lancet Respiratory Medicine | 20 days | save | | | | |
| Prostaglandin D2: the end of a story or just the beginning? | Lancet Respiratory Medicine | 22 days | save | | | | |
| Sepsis: the importance of an accurate final diagnosis | Lancet Respiratory Medicine | 25 days | save | | | | |
| Imaging research in fibrotic lung disease; applying deep learning to unsolved problems | Lancet Respiratory Medicine | 28 days | save | | | | |
| Ventilation management and clinical outcomes in invasively ventilated patients with COVID-19 (PRoVENT-COVID): a national, multicentre, observational cohort study | Lancet Respiratory Medicine | 35 days | save | | | | |
| Facemasks as a COVID-19 barrier: a window into the overlooked experience of chronic dyspnoea? | Lancet Respiratory Medicine | 35 days | save | | | | |
| Asthma in the anti-inflammatory reliever therapy era | Lancet Respiratory Medicine | 36 days | save | | | | |
| Double threat of COVID-19 and influenza | Lancet Respiratory Medicine | 36 days | save | | | | |
| Physical distancing in schools for SARS-CoV-2 and the resurgence of rhinovirus | Lancet Respiratory Medicine | 36 days | save | | | | |
| Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials | Lancet Respiratory Medicine | 38 days | save | | | | |
| Home monitoring for patients with ILD and the COVID-19 pandemic | Lancet Respiratory Medicine | 42 days | save | | | | |
| Cytokine elevation in severe and critical COVID-19: a rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes | Lancet Respiratory Medicine | 42 days | save | | | | |
| Obstructive sleep apnoea: latest surgical advances and considerations during the COVID-19 pandemic | Lancet Respiratory Medicine | 42 days | save | | | | |
| A call for Essays: stories from the frontline during the COVID-19 pandemic | Lancet Respiratory Medicine | 42 days | save | | | | |
| COVID-19 recovery: potential treatments for post-intensive care syndrome | Lancet Respiratory Medicine | 46 days | save | | | | |
| Age-sex specific pulmonary embolism-related mortality in the USA and Canada, 2000–18: an analysis of the WHO Mortality Database and of the CDC Multiple Cause of Death database | Lancet Respiratory Medicine | 46 days | save | | | | |
| Clinical impact of molecular point-of-care testing for suspected COVID-19 in hospital (COV-19POC): a prospective, interventional, non-randomised, controlled study | Lancet Respiratory Medicine | 50 days | save | | | | |
| Near-patient SARS-CoV-2 molecular platforms: new-old tools for new-old problems | Lancet Respiratory Medicine | 50 days | save | | | | |
| Diagnosis of EVALI in the COVID-19 era | Lancet Respiratory Medicine | 52 days | save | | | | |
| The changing demographics of COVID-19 | Lancet Respiratory Medicine | 52 days | save | | | | |
| Small airway loss in the physiologically ageing lung: a cross-sectional study in unused donor lungs | Lancet Respiratory Medicine | 53 days | save | | | | |
| Effect of a single day of increased as-needed budesonide–formoterol use on short-term risk of severe exacerbations in patients with mild asthma: a post-hoc analysis of the SYGMA 1 study | Lancet Respiratory Medicine | 57 days | save | | | | |
| Nebulised ALX-0171 for respiratory syncytial virus lower respiratory tract infection in hospitalised children: a double-blind, randomised, placebo-controlled, phase 2b trial | Lancet Respiratory Medicine | 60 days | save | | | | |
| Correction to Lancet Respir Med 2020; 8: 786–94 | Lancet Respiratory Medicine | 63 days | save | | | | |
| Effectiveness of fevipiprant in reducing exacerbations in patients with severe asthma (LUSTER-1 and LUSTER-2): two phase 3 randomised controlled trials | Lancet Respiratory Medicine | 64 days | save | | | | |
| Risk of COVID-19-related death among patients with chronic obstructive pulmonary disease or asthma prescribed inhaled corticosteroids: an observational cohort study using the OpenSAFELY platform | Lancet Respiratory Medicine | 64 days | save | | | | |
| Inhaled corticosteroids and COVID-19-related mortality: confounding or clarifying? | Lancet Respiratory Medicine | 64 days | save | | | | |
| Human recombinant soluble ACE2 in severe COVID-19 | Lancet Respiratory Medicine | 64 days | save | | | | |
| Hard to reach: COVID-19 responses and the complexities of homelessness | Lancet Respiratory Medicine | 65 days | save | | | | |
| COVID-19 among people experiencing homelessness in England: a modelling study | Lancet Respiratory Medicine | 65 days | save | | | | |
| COVID-19 testing in the UK | Lancet Respiratory Medicine | 66 days | save | | | | |
| Pooled saliva samples for COVID-19 surveillance programme | Lancet Respiratory Medicine | 66 days | save | | | | |
| National burden estimates of hospitalisations for acute lower respiratory infections due to respiratory syncytial virus in young children in 2019 among 58 countries: a modelling study | Lancet Respiratory Medicine | 66 days | save | | | | |
| Amazon fires coincide with increased respiratory illnesses in indigenous populations | Lancet Respiratory Medicine | 66 days | save | | | | |
| | 
report | next » |
| |
